Nachrichten zur AstraZeneca PLC Aktie

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.…

AstraZeneca’s $2 billion Summit stake wins backing from UBS and Jefferies

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2…

Brokers applaud AstraZenecas $2bn Summit bet

…

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc. as part of…

AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates…

AstraZeneca takes $2bn stake in Summit Therapeutics to pair up cancer drugs

…

Is AstraZenecas Oncology Portfolio Positioned for Continued Growth?

AZNs oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise…

Directors’ Deals: AstraZeneca’s Soriot in a major show of faith

Share price is down after a series of disappointing drug trials…

AstraZenecas Trixeo Secures Approval for Asthma in the EU

AZNs Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.…

Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note

In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.…

FDA Grants Priority Review to AZNs Filing for Rare Bone Disease Drug

AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.…

AstraZeneca shares oversold after trial flops and merger talk, says UBS

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its…

AstraZeneca Aktie: Das Sell-Signal ist weg!

Bad Marienberg (www.aktiencheck.de) - Die Deutsche Bank wird bei der AstraZeneca-Aktie vorsichtig optimistischer. In ihrer AstraZeneca-Aktienanalyse vom 15. September 2026…

AstraZenecas news flow next year could sustain drugs group beyond 2030, says leading bank

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) offers the richest run of drug news in the pharmaceuticals sector over the next 18 months,…

AstraZeneca Aktie: UBS wird nach Studienrückschlägen deutlich vorsichtiger

Bad Marienberg (www.aktiencheck.de) - Bei AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London Stock Exchange-Symbol: AZN) prallen derzeit zwei…

Why the Market Dipped But Astrazeneca (AZN) Gained Today

In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.…

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Sp

By Steven Ralston, CFANYSE: VNRXREAD THE FULL VNRX RESEARCH REPORTEXECUTIVE OVERVIEWVolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics…

AstraZeneca breast cancer drug fails trial but Citi keeps buy rating

AstraZeneca PLCs (LSE:AZN, NASDAQ:AZN) experimental breast cancer drug camizestrant has failed a late-stage trial, though analysts at Citi say the…

AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

…

AstraZenecas Etcamah fails in late-stage trial as first-line breast cancer treatment

…

AstraZeneca breast cancer drug fails late-stage trial goal

AstraZeneca breast cancer drug fails late-stage trial goal…

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

Amgen and AstraZenecas Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs reach.…

AstraZenecas $5bn drug promise is no buy signal for Deutsche

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimabs lung disease data, but the broker paired its positive…

AstraZenecas $5bn drug promise is no buy signal for Deutsche

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimabs lung disease data, but the broker paired its positive…

AstraZeneca Sell

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Astrazeneca mit einem Kursziel von 11500 Pence auf "Sell" belassen. Der Pharmakonzern…

AstraZeneca COPD data back Citis $7b peak sales case

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citis backing after tozorakimab trial results, supporting an upside case of at least $7 billion…

Amgen and AstraZeneca report positive lung cancer trial results

Amgen and AstraZeneca report positive lung cancer trial results…

Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval

Citi has flagged AstraZeneca PLCs (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment...…

Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval

Citi has flagged AstraZeneca PLCs (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment...…

AstraZeneca: Share price weakness of late, should be capitalised on

Target changeChange in target pricep 14,380 vs 15,038 -4.38%We have tweaked our earnings estimates lower and considering the recent late-stage…

CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor

By Tom Kerr, CFANASDAQ: CTSOREAD THE FULL CTSO RESEARCH REPORTNew Findings Presented at European Society of Cardiology (ESC) Congress 2026On…

dpa-AFX ProFeed